8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
The US Food and Drug Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). 30 July 2021
Johnson & Johnson’s partner for manufacturing its coronavirus vaccine, Emergent BioSolutions, has announced it will be able to resume operations at its plant in Bayview, USA. 30 July 2021
US biotech major Gilead Sciences yesterday posting financials for second-quarter 2021, showing that revenues of $6.2 billion increased 21% compared to the same period in 2020. 30 July 2021
US biotech Arrowhead Pharmaceuticals today announced that it was granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration for ARO-AAT, also known as TAK-999, the company’s second-generation investigational RNA interference (RNAi) therapeutic. 29 July 2021
The US Food and Drug Administration has revised the Emergency Use Authorization (EUA) for baricitinib, sold under the brand name Olumiant by Eli Lilly’s), now authorizing baricitinib alone for the treatment of COVID-19 in hospitalized adults and pediatric patients. 29 July 2021
The US Food and Drug Administration has accepted Roche’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the Swiss pharma giant’s submission for diabetic retinopathy. 29 July 2021
US biotech bluebird bio edged up 2% in early trading yesterday, after it announced an agreement with National Resilience to accelerate the early research, development, and delivery of next-generation cell therapies. 29 July 2021
On the same day that New York’s Pfizer released stellar second-quarter financials, the company also made public less encouraging news on the vaccine front. 29 July 2021
The US Food and Drug Administration today alerted patients and health care professionals that a clinical trial (OCEAN, Study OP-103) evaluating Pepaxto (melphalan flufenamide) with dexamethasone to treat patients with multiple myeloma showed an increased risk of death. 28 July 2021
Pfizer’s investment in developing a novel coronavirus vaccine has paid off, and then some, the firm’s second-quarter results statement reveals. 28 July 2021
The Japanese pairing of PeptiDream and Takeda have announced an expansion of their research collaboration and exclusive license agreement to create peptide-drug conjugates (PDCs) for several central nervous system (CNS) targets. 28 July 2021
For the second time since its initiation in 2014, a research partnership between AbbVie and Calico Life Sciences has been extended, bringing the total investment to over $3 billion. 28 July 2021
The USA’s largest biotech Amgen has announced its third acquisition this year, saying yesterday that it is to buy Teneobio, a California-based privately held, clinical stage biotechnology company developing a new class of biologics called human heavy-chain antibodies. 28 July 2021
Evidence from a large real-world study suggests that rare blood clotting disorders, previously associated with viral vector-based coronavirus vaccines, could also affect mRNA-based options. 28 July 2021
Marking a second licensing deal this month, French drugmaker Ipsen has signed an exclusive worldwide collaboration agreement with US biotech BAKX Therapeutics to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors. 28 July 2021
Swiss biotech AC Immune today announced that it is acquiring Austrian vaccine specialist Affiris’ portfolio of therapeutics targeting alpha-synuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson’s disease, as well as cash. 27 July 2021
Chicago, USA-based antimicrobial resistance specialist Iterum Therapeutics announced a regulatory setback for its candidate, oral sulopenem, on Monday. 27 July 2021
Edison Group’s new report Biosynthesis: Taking the cannabinoid market to new heights explores the growth potential for biosynthesis in the production of high-quality cannabinoids, following predictions that the global market for CPG and pharma cannabinoid biosynthesis products could reach $92 billion by 2040. 27 July 2021
At the Alzheimer’s Association International Conference (AAIC), taking place in Colorado, USA, newly-approved Aduhelm (aducanumab) is understandably the main focus of attention. 27 July 2021
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024
Kezar Life Sciences has paused its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 7 October 2024
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.